Recent Updates
Recently added Catalysts

THCv

Phase 1

Healthy Adults | Unknown | Other |Canopy Growth Corporation Common Shares|Last Updated: May 12, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment21
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05210634Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy ParticipantsPHASE1 COMPLETED 21Jan 1, 2022May 1, 2022May 12, 2022 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
THCvDIETARY_SUPPLEMENTTHCv in MCT oil
Unlock Study Design Details